AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT). METHODS: We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients. RESULTS: A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission. CONCLUSIONS: AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.

Full Text

Duke Authors

Cited Authors

  • Gupta, S; Coca, SG; Chan, L; Melamed, ML; Brenner, SK; Hayek, SS; Sutherland, A; Puri, S; Srivastava, A; Leonberg-Yoo, A; Shehata, AM; Flythe, JE; Rashidi, A; Schenck, EJ; Goyal, N; Hedayati, SS; Dy, R; Bansal, A; Athavale, A; Nguyen, HB; Vijayan, A; Charytan, DM; Schulze, CE; Joo, MJ; Friedman, AN; Zhang, J; Sosa, MA; Judd, E; Velez, JCQ; Mallappallil, M; Redfern, RE; Bansal, AD; Neyra, JA; Liu, KD; Renaghan, AD; Christov, M; Molnar, MZ; Sharma, S; Kamal, O; Boateng, JO; Short, SAP; Admon, AJ; Sise, ME; Wang, W; Parikh, CR; Leaf, DE; STOP-COVID Investigators,

Published Date

  • January 2021

Published In

Volume / Issue

  • 32 / 1

Start / End Page

  • 161 - 176

PubMed ID

  • 33067383

Pubmed Central ID

  • PMC7894677

Electronic International Standard Serial Number (EISSN)

  • 1533-3450

Digital Object Identifier (DOI)

  • 10.1681/ASN.2020060897


  • eng

Conference Location

  • United States